目的:评价含莫西沙星的3联疗法补救治疗幽门螺杆菌(Hp)的疗效及安全性。方法:将Hp感染经常规治疗失败的100例患者按随机数字表分为研究组(50例)和对照组(50例)。研究组患者给予以含莫西沙星的3联疗法(莫西沙星+雷贝拉唑钠肠溶片+阿莫西林),对照组患者使用4联补救疗法(雷贝拉唑钠肠溶片+胶体果胶铋+克拉霉素+甲硝唑),疗程7天,比较2组根除Hp情况。结果:研究组40例补救治疗成功;对照组35例根除治疗成功,2组的Hp根除率分别为75.5%和62.5%,其按符合方案(PP)Hp根除率分别为83.3%和71.4%,差异均无统计学意义(均P>0.05)。结论:对既往标准3联疗法治疗失败的患者,莫西沙星+阿莫西林+雷贝拉唑l周疗法PP分析Hp根除率>80%,优于常规4联补救方案。 Objective: To evaluate the efficacy and safety of triple therapy with moxifloxacin in the treatment of Helicobacter pylori (Hp). Methods: One hundred patients with Hp infection who had failed conventional treatment were divided into study group (50 cases) and control group (50 cases) according to random number table. Patients in the study group were given triple therapy with moxifloxacin (moxifloxacin + rabeprazole enteric-coated tablets + amoxicillin), and patients in the control group were treated with 4-combined salvage therapy (rabeprazole sodium enteric-coated tablets + Colloidal bismuth pectin + clarithromycin + metronidazole) for 7 days, compared with the two groups of Hp eradication. Results: In the study group, 40 cases were successfully remedied. In the control group, 35 cases were successfully treated with eradication. The Hp eradication rates in the two groups were 75.5% and 62.5%, respectively. The Hp eradication rates of the two groups were 83.3% and 71.4%, respectively, There was no significant difference (all P> 0.05). CONCLUSIONS: For the patients who failed the standard triple therapy, the Hp eradication rate was> 80% for the l-week treatment with moxifloxacin + amoxicillin + rabeprazole, which was superior to the conventional quadruple salvage regimen.